Moving away from a one-size-fits-all approach, the U.S. FDA's CBER released details Jan. 11 about how it’s leveraging its growing experience with cell and gene therapies (CGTs) to exercise greater ...

On the 12th (local time), the ‘JP Morgan Healthcare Conference’ opened in San Francisco, U.S. The biggest topic at this ...

Investors poured into a room at #JPM26 to see how Revolution Medicines' CEO would dance around questions they knew he ...

One of the major promises of artificial intelligence (AI) is its role in speeding up drug discovery. AI can process massive ...

The stimulants Ritalin and Adderall have been used to treat attention-deficit/hyperactivity disorder (ADHD) for decades, but ...

Cannabis produces a complex suite of bioactive compounds, including tetrahydrocannabinol (THC) and cannabidiol (CBD), but how ...

Both biotechs are a bit risky, but could benefit from clinical progress this year -- and the upside would be huge. CRISPR has ...

NVIDIA and Lilly bring together a world-leading, multidisciplinary team of scientists, AI researchers and engineers to ...

Eli Lilly and Nvidia, two primary drivers of the recent stock market rally, are deepening their alliance to connect silicon ...

The biopharmaceutical sector finally regained its footing in 2025. Here are 5 issues that could determine whether the renewed ...

Teva has penned a second pact with Royalty Pharma, this time securing up to $500 million to support the clinical development ...